Pharmacological interventions to attenuate muscle wasting in cancer cachexia
Wasting of skeletal muscle leads to profound weakness, reduced functional independence, and eventually death through respiratory or cardiac failure. Muscle wasting is observed during ageing and disuse, but is also associated with muscular dystrophy, sepsis, renal failure, AIDS, diabetes and cancer. In cancer, muscle loss occurs as part of the syndrome of cachexia, a debilitating condition characterised by weight loss, muscle weakness, anaemia, insulin resistance, and fatigue. Muscle atrophy in cancer patients is life-threatening and therapeutic options are limited. Preserving muscle mass is critical for survival and successful therapies have broad clinical impact across many wasting diseases. Our laboratory tests novel therapeutic targets to ameliorate the muscle wasting associated with cancer cachexia. This work is driven by Dr. Kate Murphy. Kate is an NHMRC Biomedical Research Fellow and one of Australia's leading experts in cancer cachexia.
National Health & Medical Research Council